Show simple item record

dc.contributor.authorSigurdardottir, S T
dc.contributor.authorVidarsson, G
dc.contributor.authorGudnason, T
dc.contributor.authorKjartansson, S
dc.contributor.authorKristinsson, K G
dc.contributor.authorJonsson, S
dc.contributor.authorValdimarsson, H
dc.contributor.authorSchiffman, G
dc.contributor.authorSchneerson, R
dc.contributor.authorJonsdottir, I
dc.date.accessioned2010-09-17T13:49:04Z
dc.date.available2010-09-17T13:49:04Z
dc.date.issued1997-07-01
dc.date.submitted2010-09-17
dc.identifier.citationPediatr. Infect. Dis. J. 1997, 16(7):667-74en
dc.identifier.issn0891-3668
dc.identifier.pmid9239771
dc.identifier.doi10.1097/00006454-199707000-00009
dc.identifier.urihttp://hdl.handle.net/2336/111296
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractBACKGROUND: Streptococcus pneumoniae is a major cause of meningitis, bacteremia, pneumonia and otitis media. Pneumococcal polysaccharides are not immunogenic in infants, but improved immunogenicity of polysaccharide-protein conjugates has been demonstrated. Antibiotic-resistant pneumococci have increased the need for an effective vaccine. OBJECTIVE: To study the safety and immunogenicity of a pneumococcal type 6B polysaccharidetetanus toxoid conjugate (Pn6B-TT) in infants and to assess the function of antibodies. METHODS: Healthy infants were injected, Group A at 3, 4 and 6 months (n = 21) and Group B at 7 and 9 months (n = 19). Booster injection was given at 18 months. Antibodies were measured by enzyme-linked immunosorbent assay and radioimmunoassay, and functional activity was measured by opsonization of radiolabeled pneumococci. Nasopharyngeal cultures were obtained. RESULTS: No significant adverse reactions were observed. Pn6B-IgG (enzyme-linked immunosorbent assay) increased to a geometric mean of 0.62 microgram/ml (P = 0.367, compared with prevaccination titers) in Group A at 7 months and 1.22 micrograms/ml (P < 0.001) in Group B at 10 months. Total Pn6B antibodies (radioimmunoassay) were 44 ng of antibody N/ml (P < 0.053) in Group A and 211 ng of antibody N/ml (P < 0.001) in Group B. A smaller increase in IgM and IgA anti-Pn6B was observed. Reinjection at 18 months elicited booster responses in total and IgG anti-Pn6B; 62% of those in Group A and 79% of those in Group B had > 300 ng of antibody N/ml. Opsonic activity, after initial and booster vaccinations, correlated with Pn6B-antibody titers. Three infants with nasopharyngeal cultures repeatedly positive for serogroup 6 had poor serum IgG responses. CONCLUSION: Our results demonstrate that Pn6B-TT is safe, elicits functional antibodies and memory responses in infants.
dc.language.isoenen
dc.publisherLippincott Williams & Wilkins Ltd.en
dc.relation.urlhttp://dx.doi.org/10.1097/00006454-199707000-00009en
dc.subject.meshAntibodies, Bacterialen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshImmunoglobulin A, Secretoryen
dc.subject.meshInfanten
dc.subject.meshMaleen
dc.subject.meshNasopharynxen
dc.subject.meshPhagocytosisen
dc.subject.meshPolysaccharides, Bacterialen
dc.subject.meshSalivaen
dc.subject.meshStreptococcus pneumoniaeen
dc.subject.meshTetanus Toxoiden
dc.subject.meshVaccinationen
dc.subject.meshVaccines, Conjugateen
dc.titleImmune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoiden
dc.typeArticleen
dc.contributor.departmentDepartment of Immunology, National University Hospital, Reykjavik, Iceland.en
dc.identifier.journalPediatric infectious disease journalen
html.description.abstractBACKGROUND: Streptococcus pneumoniae is a major cause of meningitis, bacteremia, pneumonia and otitis media. Pneumococcal polysaccharides are not immunogenic in infants, but improved immunogenicity of polysaccharide-protein conjugates has been demonstrated. Antibiotic-resistant pneumococci have increased the need for an effective vaccine. OBJECTIVE: To study the safety and immunogenicity of a pneumococcal type 6B polysaccharidetetanus toxoid conjugate (Pn6B-TT) in infants and to assess the function of antibodies. METHODS: Healthy infants were injected, Group A at 3, 4 and 6 months (n = 21) and Group B at 7 and 9 months (n = 19). Booster injection was given at 18 months. Antibodies were measured by enzyme-linked immunosorbent assay and radioimmunoassay, and functional activity was measured by opsonization of radiolabeled pneumococci. Nasopharyngeal cultures were obtained. RESULTS: No significant adverse reactions were observed. Pn6B-IgG (enzyme-linked immunosorbent assay) increased to a geometric mean of 0.62 microgram/ml (P = 0.367, compared with prevaccination titers) in Group A at 7 months and 1.22 micrograms/ml (P < 0.001) in Group B at 10 months. Total Pn6B antibodies (radioimmunoassay) were 44 ng of antibody N/ml (P < 0.053) in Group A and 211 ng of antibody N/ml (P < 0.001) in Group B. A smaller increase in IgM and IgA anti-Pn6B was observed. Reinjection at 18 months elicited booster responses in total and IgG anti-Pn6B; 62% of those in Group A and 79% of those in Group B had > 300 ng of antibody N/ml. Opsonic activity, after initial and booster vaccinations, correlated with Pn6B-antibody titers. Three infants with nasopharyngeal cultures repeatedly positive for serogroup 6 had poor serum IgG responses. CONCLUSION: Our results demonstrate that Pn6B-TT is safe, elicits functional antibodies and memory responses in infants.


This item appears in the following Collection(s)

Show simple item record